Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Update

Abeona Therapeutics Inc (NASDAQ:ABEO) was the target of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 2,480,000 shares, a drop of 6.8% from the January 15th total of 2,660,000 shares. Currently, 6.5% of the company’s shares are sold short. Based on an average trading volume of 273,400 shares, the short-interest ratio is presently 9.1 days.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a research note on Tuesday, October 29th. StockNews.com raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Abeona Therapeutics in a research report on Monday, November 25th.

Abeona Therapeutics Stock Performance

Shares of ABEO stock opened at $6.02 on Monday. Abeona Therapeutics has a one year low of $3.05 and a one year high of $9.01. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The stock has a market cap of $261.69 million, a PE ratio of -2.24 and a beta of 1.43. The stock has a 50-day moving average of $5.66 and a 200-day moving average of $5.79.

Hedge Funds Weigh In On Abeona Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ABEO. Northern Trust Corp raised its stake in Abeona Therapeutics by 6.6% during the 4th quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company’s stock worth $1,030,000 after buying an additional 11,478 shares during the period. Jane Street Group LLC acquired a new stake in shares of Abeona Therapeutics during the third quarter worth about $84,000. Oxford Asset Management LLP bought a new position in shares of Abeona Therapeutics during the 4th quarter valued at about $118,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Abeona Therapeutics in the 3rd quarter valued at approximately $151,000. Finally, XTX Topco Ltd bought a new stake in Abeona Therapeutics during the 3rd quarter worth approximately $160,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.